Company intelligence / Profile preview

Cyvek

Wallingford, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Cyvek is a life science technology company that developed the CyPlex platform, an automated, benchtop immunoassay system designed for rapid, multiplexed protein analysis. The technology utilizes microfluidic cartridges to provide high-sensitivity results with minimal hands-on time, significantly improving workflow efficiency compared to traditional ELISA methods. In 2014, Cyvek was acquired by Bio-Techne and integrated into its ProteinSimple division. The core technology now powers the Ella automated immunoassay system, which is widely used in clinical research and biopharmaceutical development. The platform is known for its 'Simple Plex' assays, which offer high reproducibility and a wide dynamic range for biomarker detection.

Modalities: Device
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Cyvek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyvek.

Explore the full profile